Latest news with #ADIA
Yahoo
an hour ago
- Business
- Yahoo
The Convergence of TradFi and Digital Asset Markets
The line between traditional and crypto markets is actively being redrawn. As digital asset markets mature, the convergence of traditional finance (TradFi) and digital markets is accelerating, resulting in a more mature, institutional-grade ecosystem shaped by the frameworks, expectations and operational resilience that have historically characterized TradFi. Recent developments underscore a paradigm shift in how digital assets are perceived by institutions. The U.S. government's announcement of a strategic digital asset reserve, consisting of bitcoin, ether, XRP, solana and cardano, signals strong institutional validation. In parallel, more than eleven U.S. states have shown interest in or are actively working on bitcoin treasury bills. Sovereign investors such as the Abu Dhabi Investment Authority (ADIA) have disclosed significant positions, with a $436.9 million stake in BlackRock's iShares Bitcoin ETF (IBIT) as of December 31, 2024. These aren't speculative moves, but rather concerted investments to stay at the forefront of an evolving financial system. Support from these governments is reinforcing institutional engagement, marking a turning point where the risk of missing out outweighs the risk of exposure to the digital assets ecosystem. Previously, institutional participation in digital assets was constrained by high volatility, regulatory uncertainty and fragmented infrastructure. Now, regulated custodians offer institutional-grade solutions, while trading platforms provide improved access and reliable execution. The expansion of risk management tools — including hedging, credit facilities and market surveillance — has enhanced the operational stability for a space once known for volatility. These developments have lowered barriers to entry, enabling traditional institutions to approach digital assets with familiar risk and compliance frameworks. Institutional adoption is further fueled by products that mirror traditional markets while leveraging blockchain advantages. Today's institutional offerings include spot & derivatives markets, yield-bearing products, ETFs & in-kind redemptions and depositary receipts — all designed with similar underwriting logic and performance expectations. The expansion of futures, options and structured products in crypto mirrors the mechanics of TradFi derivatives. These instruments provide price discovery, risk hedging and speculative capabilities that align with institutional mandates. Yield-bearing products like staking, crypto lending and tokenized fixed-income are being designed with yield profiles resembling TradFi. These structures provide fixed or floating returns while incorporating risk metrics familiar to institutions. One of the most popular products has been spot bitcoin ETPs. Nasdaq's proposed in-kind redemptions for BlackRock's Bitcoin ETF further align crypto ETFs with traditional counterparts, boosting efficiency and liquidity. Additionally, crypto depositary receipts enable institutions to access digital assets without direct custody, bridging traditional markets and crypto in a regulated, familiar structure. Institutional investors are engaging through structures that blend traditional and digital techniques: hybrid funds, separately managed accounts (SMAs) and bespoke mandates. These tailor exposure while maintaining operational familiarity, providing institutions with regulated pathways to participate in this evolving ecosystem. Regulatory clarity remains critical. Recent SEC moves and a more crypto-forward administration signal openness to clearer frameworks, encouraging increased institutional engagement. Some traditional players are still taking a wait-and-see approach, cautiously observing market infrastructure and regulatory signals before committing capital at scale. On the other hand, firms like BlackRock, Fidelity and Citadel are entering the DeFi space. Institutional adoption is unlocking portfolio diversification, enhanced market efficiency and a more structured approach to risk management, all pointing to a more robust financial ecosystem. The institutionalization of digital assets and its convergence with traditional financial systems is not a passing trend, but a structural realignment of markets. Forward-looking institutions are not just participating, they're supporting the emerging ecosystem. For CIOs and allocators, this convergence presents an inflection point. The ability to navigate digital assets with TradFi discipline and DeFi innovation is becoming a key differentiator — placing emphasis on the importance of partnering with firms who have deep experience across both markets. As the financial landscape evolves, institutions that stay informed and insightful will find themselves positioned to adapt and thrive. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Economic Times
a day ago
- Business
- Economic Times
Peak XV trims stake in Zinka Logistics in Rs 302 crore bulk deal; ADIA, MIT among buyers
Live Events (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel Bengaluru-based logistics tech company Zinka Logistics Solutions , popularly known as BlackBuck, witnessed a block deal on Tuesday. A group of marquee institutional investors picked up stakes, while existing investor Peak XV Partners pared down its holding. The total block deal value is around Rs 302 to data from the stock exchanges, nearly 59 lakh shares changed hands. Among the buyers were global institutional names such as Abu Dhabi Investment Authority (ADIA), ICICI Prudential Mutual Fund, and Massachusetts Institute of Technology (MIT).ADIA purchased 23,02,574 shares at a price of Rs 420 per share. ICICI Prudential Mutual Fund acquired 11,42,856 shares at the same price, while MIT picked up the largest chunk -- 24,65,945 shares -- at Rs 420 per the sell side, Peak XV Partners Investments VI offloaded 12,10,588 shares at a higher price of Rs 444.71 per share, likely booking gains on their earlier of the latest available data, promoters held 27.7% of Zinka, while the public held 72.3%. Foreign investors made up a large chunk of the public shareholding, with several high-profile names such as Tribe Capital, Sands Capital, Accel, and B Capital featuring on the largest public shareholder was Quickroutes International, holding over 9% stake. Among mutual funds, SBI Technology Opportunities Fund held 6.62%, while Bandhan Core Equity Fund and Invesco India Contra Fund held smaller Logistics is one of India's leading tech-driven logistics platforms specializing in full-truck load (FTL) freight. Founded in 2015, the company has transformed the traditional trucking ecosystem by digitizing operations for both fleet owners and its mobile and web-based solutions, Zinka connects truckers with businesses in real-time, offering seamless booking, GPS-based tracking, digital payments, and documentation. The platform serves a wide range of industries including FMCG, manufacturing, and e-commerce, providing reliable long-haul transportation across company also assists truckers with services like fuel cards, insurance, and toll management, aiming to improve their efficiency and reduce idle time.(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)
Time of India
a day ago
- Business
- Time of India
Peak XV trims stake in Zinka Logistics in Rs 302 crore bulk deal; ADIA, MIT among buyers
Live Events (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel Bengaluru-based logistics tech company Zinka Logistics Solutions , popularly known as BlackBuck, witnessed a block deal on Tuesday. A group of marquee institutional investors picked up stakes, while existing investor Peak XV Partners pared down its holding. The total block deal value is around Rs 302 to data from the stock exchanges, nearly 59 lakh shares changed hands. Among the buyers were global institutional names such as Abu Dhabi Investment Authority (ADIA), ICICI Prudential Mutual Fund, and Massachusetts Institute of Technology (MIT).ADIA purchased 23,02,574 shares at a price of Rs 420 per share. ICICI Prudential Mutual Fund acquired 11,42,856 shares at the same price, while MIT picked up the largest chunk -- 24,65,945 shares -- at Rs 420 per the sell side, Peak XV Partners Investments VI offloaded 12,10,588 shares at a higher price of Rs 444.71 per share, likely booking gains on their earlier of the latest available data, promoters held 27.7% of Zinka, while the public held 72.3%. Foreign investors made up a large chunk of the public shareholding, with several high-profile names such as Tribe Capital, Sands Capital, Accel, and B Capital featuring on the largest public shareholder was Quickroutes International, holding over 9% stake. Among mutual funds, SBI Technology Opportunities Fund held 6.62%, while Bandhan Core Equity Fund and Invesco India Contra Fund held smaller Logistics is one of India's leading tech-driven logistics platforms specializing in full-truck load (FTL) freight. Founded in 2015, the company has transformed the traditional trucking ecosystem by digitizing operations for both fleet owners and its mobile and web-based solutions, Zinka connects truckers with businesses in real-time, offering seamless booking, GPS-based tracking, digital payments, and documentation. The platform serves a wide range of industries including FMCG, manufacturing, and e-commerce, providing reliable long-haul transportation across company also assists truckers with services like fuel cards, insurance, and toll management, aiming to improve their efficiency and reduce idle time.(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)
National Post
27-05-2025
- Business
- National Post
Galderma Intends to Buy Back approximately 2.4 Million Shares in the Context of the Accelerated Bookbuild Offering by EQT, ADIA and Auba
Article content ZUG, Switzerland — Galderma Group AG (SWX:GALD): Article content Article content Galderma intends to repurchase approximately 2.4 million shares in the context of the accelerated bookbuild offering of Galderma shares by Sunshine SwissCo GmbH ('EQT'), Abu Dhabi Investment Authority ('ADIA') and Auba Investment Pte. Ltd. ('Auba') announced today The repurchased shares will be held in treasury and financed by existing liquidity at hand Article content Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it intends to repurchase approximately 2.4 million Galderma shares in the context of an accelerated bookbuilding offering ('ABO') of approximately 16.7 million Galderma shares (approximately 7% of Galderma's share capital) by EQT, ADIA and Auba. Galderma will participate in the ABO at the same price per share which will be determined in the bookbuilding. Article content The repurchased shares will be financed by Galderma's existing liquidity on hand and will not affect the company's ability to deliver on its strategic and financing priorities. Article content The shares will be held in treasury for future use in connection with Galderma's employee participation plans, business development opportunities and/or treasury management. Article content About Galderma Article content Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body's largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: Article content Certain statements in this announcement are forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as 'plans', 'targets', 'aims', ' believes', 'expects', 'anticipates', 'intends', 'estimates', 'will', 'may', 'continues', 'should' and similar expressions. These forward-looking statements reflect, at the time, Galderma's beliefs, intentions and current targets/ aims concerning, among other things, Galderma's results of operations, financial condition, industry, liquidity, prospects, growth and strategies and are subject to change. The estimated financial information is based on management's current expectations and is subject to change. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial consequences of the plans and events described herein. Actual results may differ from those set forth in the forward-looking statements as a result of various factors (including, but not limited to, future global economic conditions, changed market conditions, intense competition in the markets in which Galderma operates, costs of compliance with applicable laws, regulations and standards, diverse political, legal, economic and other conditions affecting Galderma's markets, and other factors beyond the control of Galderma). Neither Galderma nor any of their respective shareholders (as applicable), directors, officers, employees, advisors, or any other person is under any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward-looking statements, which speak of the date of this announcement. Statements contained in this announcement regarding past trends or events should not be taken as a representation that such trends or events will continue in the future. Some of the information presented herein is based on statements by third parties, and no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, reasonableness, accuracy, completeness or correctness of this information or any other information or opinions contained herein, for any purpose whatsoever. Except as required by applicable law, Galderma has no intention or obligation to update, keep updated or revise this announcement or any parts thereof. Article content Article content Article content Article content Contacts Article content For further information: Article content Christian Marcoux, Chief Communications Officer +41 76 315 26 50 Article content Richard Harbinson Corporate Communications Director +41 76 210 60 62 Article content Emil Ivanov Head of Strategy, Investor Relations, and ESG +41 21 642 78 12 Article content Article content Article content
Mint
26-05-2025
- Business
- Mint
Warburg bet on this company three years ago. Now Temasek, ADIA are lining up.
Warburg Pincus-backed Micro Life Sciences Pvt. Ltd is in advanced talks to raise capital from Singapore's Temasek Holdings and the UAE's Abu Dhabi Investment Authority (ADIA) ahead of a planned initial public offering (IPO), three people aware of the development said. 'The current funding round is expected to be around $250-300 million," one of the people cited above said. The company is likely to go public over the next 12-18 months, the second person added. 'The (valuation) ask is around ₹65,000 crore, which is more than 40 times its Ebitda," the third person said, adding the company reported an earnings before interest, tax, depreciation and amortization or Ebitda of around ₹1,300 crore in FY25. All three people spoke on the condition of anonymity. Also read | Temasek-backed Manipal Health eyes a $1 bn IPO, calls banker pitches Temasek, ADIA, and Warburg Pincus declined to comment on Mint's queries, while a response from Micro Life was unavailable until press time. The Vapi, Gujarat-based Bilakhia family founded Micro Life Sciences in 2006. The company has multiple subsidiaries, with the most prominent being Meril Life Sciences. The Bilakhia group, founded by Gafurbhai Bilakhia, is now managed by his three sons, Yunus Bilakhia, Jakir Bilakhia and Anjum Bilakhia. The company operates in healthcare, investment and real estate through its subsidiaries. Individually evaluating 'Investment firms are individually evaluating, and bids are likely to go in next month," the third person added. At a valuation of ₹65,000 crore, Warburg Pincus, which invested $210 million in Micro Life three years ago at a valuation of over $1.8 billion, may be sitting on a fourfold gain in its investment. 'At that value, only a sovereign fund or a state-backed investor can do a deal, given their cost of capital is low," the third person said. Also read | IDFC First Bank to raise ₹7,500 crore from Warburg Pincus, ADIA Meril, a key subsidiary of Micro Life, makes coronary stents, peripheral stents, balloon catheters, and heart valves. Micro Life Sciences reported a total income of ₹3,495 crore in FY24, against ₹2,359 crore in FY23, according to a Care Ratings report dated 8 October, 2024. It reported a profit after tax of ₹333 crore in FY24, against ₹505 crore in FY23. Profit in FY23 included a 'fair value gain of ₹298 crore from the derecognition of JV investment,' Care Ratings said. 'In terms of sales mix, in FY24, Micro earned ~40% of its revenue from cardiac implants (major products: stents, balloon and heart valves), 40% from orthopaedic implants (major products: knee implants, hip implants, and surgical robots) and 10% each from the diagnostic segment and the surgical segment (major products: sutures and mechanical closures)," the note said. The report added that in some segments, the company saw 'stable to marginally higher sales realization", leading to better gross margins. Micro's gross margins improved to 72.80% in FY24 from 64.64% in FY23 on better product mix. Arms in 25 countries The Micro group has subsidiaries in more than 25 countries including Germany, Turkey, the US, Russia, South Africa, Brazil, Bangladesh, Australia, China, and the UK. The company sells its products in over 100 countries directly and through its overseas subsidiaries, with export sales realization being much higher than domestic. Also read | Haldiram's confirms stake sale to IHC, Alpha Wave Global post Temasek deal The Indian medtech ecosystem has seen tremendous investor interest in recent years. In 2024, KKR won a bidding war to acquire Healthium from Apax Partners, while Warburg Pincus invested over $300 million in Appaswamy Associates. Morgan Stanley Private Equity Asia invested ₹1,000 crore in Maiva Pharma, an injectables maker.
